Intellia Therapeutics, Inc. (NTLA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 26, 2026, announces the financial results and business updates for Intellia Therapeutics, Inc. for the quarter and full year ended December 31, 2025. The detailed results are contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the cover page text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to Exhibit 99.1 for comparative financial analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the cover page text. This information is furnished within the press release attached as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the status of clinical trials and pipeline updates mentioned in the business update section of the press release.
- Confirm any changes to financial guidance or capital raise activities disclosed in the full announcement.
- Check for any new risk factors or legal contingencies disclosed in the detailed report.